Secondary acute myeloid leukemia, also known as sAML, is a difficult-to-treat disease with traditionally poor outcomes.

sAML has been historically associated with poor outcomes. It is important to properly identify sAML and consider a treatment plan with curative intent for appropriate patients. Treating these patients with chemotherapy plus HSCT is an opportunity to improve outcomes.

Rethink sAML

Proactively identifying sAML subtypes helps ensure patients are receiving a treatment that gives them the best opportunity for long-term success.

Patients suffering from t-AML or AML-MRC have traditionally not experienced positive treatment outcomes, with the 5-year relative survival rate for patients 65 and older being only 5%.

Properly identifying sAML subtypes helps hematologists/oncologists in determining appropriate treatment, but therapy often begins without further testing or identification. This can lead to sAML patients receiving treatment approaches not focused on curative intent.

The Rethink sAML campaign emphasizes the importance of identifying subtypes and the potential impact on outcomes.

This campaign provides a compelling rationale for identifying sAML subtypes and the need for more specialized treatment. The Rethink sAML campaign challenges hematologists/oncologists to do just that—to relook at sAML patients by identifying subtypes that could help these underserved patients receive treatment focused on improved long-term outcomes.

The headline, coupled with the patient type, is a direct call-to-action to think differently about the potential of sAML patients when evaluating treatment possibilities.

Rethink sAML was a multichannel initiative that included print ads, emails, and digital advertising that drove viewers to the educational microsite Additionally, multiple elevator wraps featured components of the campaign and statistics about sAML at the 2019 Society of Hematologic Oncology (SOHO) Annual Meeting.

Planning your next project?

Work with us

Download our fact sheet

Click here